Zhou Y, Khan M, Jiang L, Fu C, Dong Y, Luo L, et al
These compounds have been also tested in two now completed phase-II and -III trials for the treatment of systemic lupus erythematosus [310] and diabetes mellitus type 1 [311] respectively, showing progressive improvement in disease activity thereby opening the way for new treatment perspectives
Other GLP1 receptor agonists, such as Trulicity (dulaglutide), Wegovy (also semaglutide but at a higher dose for weight loss), and Victoza (liraglutide), offer similar mechanisms but vary in dosing frequency, cost, and clinical indications
This reduction in ROS might be crucial, as oxidative stress is considered a key factor in cellular aging